Clinical trials: Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Acute Bacterial Skin and Skin Structure Infection
Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI
The aim of this study is to collect the data on the effectiveness of dalbavancin in terms of save of hospitalization days on patients treated between June 2017 and June 2019 in two countries (Italy and Greece) vs the other…
- Trial name
- REDS (NCT04298463)
- Testing
- Xydalba, vancomycin, teicoplanin or daptomycin
- Where
- 16 sites in Greece, Italy
- Volunteers
- 184 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Prosthetic Joints Infection (PJI)
Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants
This is a phase 1, single-center, randomized, double-blind, placebo-controlled, dose-escalation clinical trial of single and multiple intravenous doses of TNP-2092 for injection in healthy Chinese participants.
- Trial name
- NCT06394518
- Testing
- TNP-2092 for injection
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics Inc.
Skin and Subcutaneous Tissue Bacterial Infections
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
This is a randomized, double-blind, double-dummy, multicenter, global Phase 3 study of IV to oral TR-701 FA 200 mg once daily for 6 days versus IV to oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of…
- Trial name
- NCT01421511
- Testing
- TR-701 FA, Linezolid
- Where
- 117 sites in United States, Argentina and 9 more
- Volunteers
- 666 people
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Bacterial Skin and Skin Structure Infections
Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
This study will evaluate a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) for the treatment of ABSSSI compared to usual care.
- Trial name
- NCT02961764
- Testing
- Usual Care, Dalbavancin
- Where
- 11 sites in United States
- Volunteers
- 313 people
- Sponsor
- Allergan
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by…
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
- Trial name
- NCT02814916
- Testing
- Dalbavancin, Vancomycin, Oxacillin
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 199 people
- Sponsor
- AbbVie
Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA), (Susceptible or Methicillin Resistant)
Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus
The study investigates the safety and efficacy of PMX-30063 in patients treated for acute bacterial skin and skin-structure infection (ABSSSI).
- Trial name
- NCT01211470
- Testing
- Daptomycin, PMX-30063-investigational drug
- Where
- 8 sites in Canada, Russia and 1 more
- Volunteers
- 215 people
- Sponsor
- PolyMedix, Inc.
Bacterial Infections
MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections
- Trial name
- ABSSSI (NCT02269319)
- Testing
- MRX-I, Linezolid
- Volunteers
- 120 people
- Sponsor
- MicuRx
Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The purpose of this study is to evaluate the effects of Delafloxacin versus Vancomycin plus Aztreonam in the treatment of patients with acute bacterial skin and soft tissue infections.
- Trial name
- NCT01984684
- Testing
- delafloxacin, vancomycin, aztreonam
- Where
- 94 sites in United States, Argentina and 14 more
- Volunteers
- 850 people
- Sponsor
- Melinta Therapeutics, Inc.
Skin and Subcutaneous Tissue Bacterial Infections, Wound Infection
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci
The purpose of the study is to determine the safety, tolerability and effectiveness of AFN-12520000 for in the treatment of Staphylococcal infections of the skin.
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections, Wound Infection, Cutaneous Abscess, Burn Infection
- Trial name
- NCT01519492
- Testing
- AFN-12520000
- Where
- 14 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- Affinium Pharmaceuticals, Ltd
Acute Bacterial Skin and Skin Structure Infections
A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)
This study will evaluate the safety, tolerability, and efficacy of tedizolid phosphate (MK-1986) compared with comparator antibacterial agent in participants from birth to less than 12 years of age with acute bacterial skin and…
- Trial name
- NCT03176134
- Testing
- Tedizolid phosphate, Comparator
- Where
- 58 sites in United States, Brazil and 12 more
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Bacterial Skin and Skin Structure Infections
Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
This is a phase III, multi-center, randomized, active-comparator, study in subjects with ABSSSI. The study has two subgroups for assessment of efficacy and safety - oral subgroup 1 and IV subgroup 2.
- Trial name
- NCT03405064
- Testing
- Oral Levonadifloxacin/Linezolid Tablet, Intravenous Levonadifloxacin/Linezolid Infusion
- Where
- 32 sites in India
- Volunteers
- 501 people
- Sponsor
- Wockhardt